The stakes are getting significantly higher for the battle between Eli Lilly and Novo Nordisk for matchless quality in the multibillion-dollar corpulence market. Lilly on Friday unobtrusively enlisted another stage 3b preliminary on clinicaltrials.gov. The review, coded Conquer 5, will set Lilly's Mounjaro in opposition to Novo's Wegovy in patients with corpulence or overweight with weight-related ailments. The preliminary expects to enlist 700 members from 61 locales in the U.S., Canada, South America and a few European nations, as per the post. The review is at present expected to authoritatively begin next Friday and keep going for around 78 weeks, with an expected essential fulfillment date in February 2025. On the review's essential endpoint, specialists will look at the rate weight changes between the two medications by week 72 from gauge. In any case, it's not quickly evident whether Lilly is planning Overcome 5 as a prevalence concentrate on over show Mounjaro i...